These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 17018302)

  • 1. Late relapse of metastatic non-seminomatous testicular germ cell tumours.
    Rutherford EE; Ferguson JL; Geldart TR; Mead GM; Smart JM; Tung KT
    Clin Radiol; 2006 Nov; 61(11):907-15. PubMed ID: 17018302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of patients with nonseminomatous germ cell tumours and negative postchemotherapy positron emission tomography.
    Buchler T; Simonova K; Fencl P; Jarkovsky J; Abrahamova J
    Cancer Invest; 2012 Jul; 30(6):487-92. PubMed ID: 22506657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases.
    Joice GA; Rowe SP; Gorin MA; Pierorazio PM
    Curr Urol Rep; 2018 Nov; 19(12):110. PubMed ID: 30413968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Has lymphography a role in early stage testicular germ cell tumours?
    Stephenson NJ; Sandeman TF; McKenzie AF
    Australas Radiol; 1995 Feb; 39(1):54-7. PubMed ID: 7695529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Surgery of residual masses after chemotherapy in patients with testicular cancer].
    Fléchon A; Rivoire M; Berger N
    Rev Prat; 2007 Feb; 57(4):389-98. PubMed ID: 17455741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic Mature Teratoma and Growing Teratoma Syndrome in Patients with Testicular Non-Seminomatous Germ Cell Tumors.
    Green DB; La Rosa FG; Craig PG; Khani F; Lam ET
    Korean J Radiol; 2021 Oct; 22(10):1650-1657. PubMed ID: 34402242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Urologic treatment of testicular germ cell cancer].
    Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
    Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late relapse of testicular germ-cell tumours after radiotherapy.
    Lancet; 1985 Nov; 2(8464):1125. PubMed ID: 2865593
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of CT scanning in the surveillance of testicular tumours.
    Nathan PD; Rustin GR
    Clin Oncol (R Coll Radiol); 2003 May; 15(3):121-2. PubMed ID: 12801048
    [No Abstract]   [Full Text] [Related]  

  • 10. Computed tomography in the staging of testicular neoplasms.
    Lee JK; McClennan BL; Stanley RJ; Sagel SS
    Radiology; 1979 Feb; 130(2):387-90. PubMed ID: 216053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late relapse of a non-seminomatous germ cell tumour from residual mature teratoma.
    Van den Brande J; Schrijvers D; Vroman P; Prove A; Van Schil P; Becquart D; Van Marck E; Van Oosterom AT
    Acta Clin Belg; 1998 Jun; 53(3):193-7. PubMed ID: 9701855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure.
    Geldart TR; Gale J; McKendrick J; Kirby J; Mead G
    BJU Int; 2006 Aug; 98(2):353-8. PubMed ID: 16879677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of residual masses after chemotherapy in patients with non-seminomatous germ cell tumours.
    Napier MP; Naraghi A; Christmas TJ; Rustin GJ
    Br J Cancer; 2000 Nov; 83(10):1274-80. PubMed ID: 11044349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late relapse (>2 years) on surveillance in stage I non-seminomatous germ cell tumours; predominant seminoma only histology.
    Nolan L; Wheater M; Kirby J; Simmonds P; Mead G
    BJU Int; 2010 Dec; 106(11):1648-51. PubMed ID: 20735393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current management of stage I testicular non-seminomatous germ cell tumours.
    Pectasides D; Pectasides E; Constantinidou A; Aravantinos G
    Crit Rev Oncol Hematol; 2009 May; 70(2):114-23. PubMed ID: 18805019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CT and pathologic predictive features of residual mass histologic findings after chemotherapy for nonseminomatous germ cell tumors: can residual malignancy or teratoma be excluded?
    Stomper PC; Kalish LA; Garnick MB; Richie JP; Kantoff PW
    Radiology; 1991 Sep; 180(3):711-4. PubMed ID: 1651526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG-PET in the management of germ cell tumor.
    De Giorgi U; Pupi A; Fiorentini G; Rosti G; Marangolo M
    Ann Oncol; 2005 May; 16 Suppl 4():iv90-94. PubMed ID: 15923438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contemporary management of postchemotherapy testis cancer.
    Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
    Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical study of six cases showing late relapse of germ cell tumors.
    Muramaki M; Hara I; Miyake H; Yamada Y; Kawabata G; Kamidono S
    Int J Urol; 2005 Sep; 12(9):855-8. PubMed ID: 16201988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late relapses (>2 years) in patients with stage I testicular germ cell tumors: predictive factors and survival.
    Fedyanin M; Tryakin A; Kanagavel D; Bulanov A; Burova A; Figurin K; Fainshtein I; Sergeev U; Zakharova T; Garin A; Tjulandin S
    Urol Oncol; 2013 May; 31(4):499-504. PubMed ID: 21803619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.